Updated: March 29, 2026
Ceftriaxone Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Get the latest on the Ceftriaxone shortage in 2026. Learn what's causing limited supply, how much it costs, and how to find it in stock near you.
The Ceftriaxone Shortage in 2026: What's Going On?
If you've been prescribed Ceftriaxone recently, you may have run into an unexpected problem: your hospital, clinic, or pharmacy doesn't have it. Ceftriaxone — one of the most commonly used injectable antibiotics in the United States — has been affected by intermittent supply shortages that began in late 2023 and have continued into 2026.
This update covers the current state of the shortage, what's causing it, how much Ceftriaxone costs in 2026, and what you can do to get the treatment you need.
Is Ceftriaxone Still in Shortage?
Yes. As of early 2026, certain Ceftriaxone formulations remain in limited supply. The shortage has particularly affected:
- Premixed IV bags (1 g/50 mL and 2 g/50 mL in dextrose) — these ready-to-use bags are the most convenient formulation for hospitals and infusion centers, and have been the hardest hit
- Specific vial strengths — availability varies by manufacturer, with some strengths (like 250 mg and 2 g) more affected than others
The situation is not a complete nationwide outage. Powder-for-injection vials (1 g and 500 mg) are more widely available, and supply has gradually improved in some regions. However, many facilities still report difficulty sourcing all the formulations they need.
The FDA and ASHP (American Society of Health-System Pharmacists) continue to track the shortage. Multiple generic manufacturers — including Sandoz, Hikma, Apotex, Fresenius Kabi, WG Critical Care, and Baxter — are working to increase production.
Why Is Ceftriaxone Hard to Find?
Several factors have combined to create and sustain this shortage:
Manufacturing Challenges
Ceftriaxone is a sterile injectable product that must be manufactured under strict FDA-regulated conditions. Production disruptions at any single plant — whether from equipment failures, quality control issues, or facility upgrades — can significantly reduce national supply. Because only a handful of companies make generic Ceftriaxone, each manufacturer's output matters enormously.
Supply Chain Vulnerabilities
The active pharmaceutical ingredients (APIs) for Ceftriaxone are primarily produced in India and China. Global supply chain disruptions — including regulatory actions at overseas manufacturing plants, shipping delays, and geopolitical tensions — have affected the steady flow of raw materials to U.S. manufacturers.
Growing Demand
Ceftriaxone demand has risen as clinical guidelines increasingly recommend it as a first-line treatment for community-acquired pneumonia, gonorrhea, and other common infections. Emergency departments, in particular, use enormous volumes of this antibiotic.
Industry Consolidation
The number of companies manufacturing generic sterile injectables has decreased over the past decade due to mergers, acquisitions, and plant closures. Fewer manufacturers means less production capacity and less resilience when problems arise.
For more background on why this medication is hard to find, see: Why Is Ceftriaxone So Hard to Find?
How Much Does Ceftriaxone Cost in 2026?
Ceftriaxone is available only as a generic (the brand name Rocephin has been discontinued), which generally keeps costs lower. However, pricing varies widely depending on formulation and where you get it:
- Powder vials (1 g): Average retail price around $52 per vial without insurance. With discount cards like GoodRx or SingleCare, prices can drop to $5 to $10 per vial.
- Premixed IV bags: Retail prices range from $20 to $60 per bag depending on the strength and supplier.
- Hospital administration: When Ceftriaxone is given in a hospital or infusion center, the drug cost is typically bundled into your facility charges and billed under your medical benefit — not your pharmacy benefit.
If you're paying out of pocket, see our detailed guide on How to Save Money on Ceftriaxone in 2026.
Are There New Options in 2026?
While no new brand-name version of Ceftriaxone has launched, there are some developments that may help patients:
- Expanded generic production: Several manufacturers have increased their production capacity for Ceftriaxone vials in response to the shortage
- FDA expedited reviews: The FDA has been working with manufacturers to expedite approval of additional production lines and new generic applications for sterile injectables
- Alternative antibiotic availability: Supply of alternative antibiotics like Cefotaxime and Cefepime has improved in some areas, giving doctors more flexibility when Ceftriaxone is unavailable
If your doctor needs to consider switching your treatment, we've covered the options: Alternatives to Ceftriaxone If You Can't Fill Your Prescription.
How to Find Ceftriaxone in Stock
If you need Ceftriaxone now, here's what to do:
- Check Medfinder: Visit medfinder.com to search for real-time Ceftriaxone availability at pharmacies, hospitals, and infusion centers near you.
- Call independent pharmacies: Smaller pharmacies often have access to different supply channels than the major chains.
- Ask about hospital outpatient services: Hospitals may have Ceftriaxone in stock through their own purchasing agreements even when retail pharmacies don't.
- Check with home health agencies: If you're on outpatient IV therapy, home health companies maintain their own drug inventories.
- Talk to your doctor: If Ceftriaxone truly isn't available, your doctor can help you explore alternatives or adjust your treatment plan.
For a complete walkthrough, read: How to Find Ceftriaxone in Stock Near You.
Final Thoughts
The Ceftriaxone shortage is frustrating, but it's not hopeless. Supply is gradually improving, and there are effective alternatives available for most infections that Ceftriaxone treats. The most important thing you can do is stay in close contact with your healthcare provider and use tools like Medfinder to track availability in your area.
We'll continue to update this page as the shortage situation evolves. Bookmark it and check back for the latest information.
Related Ceftriaxone resources:
Frequently Asked Questions
Yes. As of early 2026, certain Ceftriaxone formulations — especially premixed IV bags — remain in limited supply. Powder-for-injection vials are more widely available but may still be difficult to find in some areas. The FDA and ASHP continue to monitor the situation.
There is no confirmed end date. The shortage began in late 2023 and has persisted due to manufacturing challenges and supply chain issues. Several manufacturers have increased production, and supply is gradually improving, but complete resolution depends on sustained manufacturing capacity across all formulations.
The average retail price for a 1 g Ceftriaxone vial is approximately $52 without insurance. With discount cards like GoodRx or SingleCare, you may pay as little as $5 to $10 per vial. Premixed IV bags range from $20 to $60 each. Hospital-administered doses are typically billed under your medical benefit.
Yes. Common alternatives include Cefotaxime (a very similar third-generation cephalosporin), Cefepime (a fourth-generation cephalosporin with broader coverage), and Ertapenem (a carbapenem for resistant infections). Your doctor will choose the best alternative based on your specific infection and medical history.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsRelated articles
29,475 have already found their meds with Medfinder.
Start your search today.

![Who Has Vyvanse in Stock Near You? Find It Today [2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1079f61f167dcbc2ed5f1da17a0dcb0b7166357e-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)



